These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
704 related articles for article (PubMed ID: 15577851)
1. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis. Limaye AP; Abrams JS; Silver JE; Awadzi K; Francis HF; Ottesen EA; Nutman TB J Clin Invest; 1991 Oct; 88(4):1418-21. PubMed ID: 1918387 [TBL] [Abstract][Full Text] [Related]
3. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. Busse WW; Ring J; Huss-Marp J; Kahn JE J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668 [TBL] [Abstract][Full Text] [Related]
10. Eosinophilic myositis with eosinophilic cellulitislike skin lesions. Association with increased serum levels of eosinophil cationic protein and interleukin-5. Trüeb RM; Lübbe J; Torricelli R; Panizzon RG; Wüthrich B; Burg G Arch Dermatol; 1997 Feb; 133(2):203-6. PubMed ID: 9041834 [TBL] [Abstract][Full Text] [Related]
11. [Dysregulation of cooperative interactions of immunocytes and eosinophils in the mechanism of development of eosinophilia in Opisthorhis felineus invasion]. Litvinova LS; Riazantseva NV; Novitskiĭ VV Med Parazitol (Mosk); 2008; (3):13-7. PubMed ID: 18819423 [TBL] [Abstract][Full Text] [Related]
12. Conjunctival fibroblasts enhance the survival and functional activity of peripheral blood eosinophils in vitro. Solomon A; Shmilowich R; Shasha D; Frucht-Pery J; Pe'er J; Bonini S; Levi-Schaffer F Invest Ophthalmol Vis Sci; 2000 Apr; 41(5):1038-44. PubMed ID: 10752939 [TBL] [Abstract][Full Text] [Related]
13. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Schwartz LB; Sheikh J; Singh A Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230 [TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Kay AB; Klion AD Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864 [TBL] [Abstract][Full Text] [Related]
15. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Kips JC; O'Connor BJ; Langley SJ; Woodcock A; Kerstjens HA; Postma DS; Danzig M; Cuss F; Pauwels RA Am J Respir Crit Care Med; 2003 Jun; 167(12):1655-9. PubMed ID: 12649124 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-5 mRNA levels in blood and bone marrow mononuclear cells from patients with the idiopathic hypereosinophilic syndrome. Satoh T; Sun L; Li MS; Spry CJ Immunology; 1994 Oct; 83(2):308-12. PubMed ID: 7835952 [TBL] [Abstract][Full Text] [Related]
17. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Daikh BE; Ryan CK; Schwartz RH Ann Allergy Asthma Immunol; 2003 Jan; 90(1):23-7. PubMed ID: 12546333 [TBL] [Abstract][Full Text] [Related]